Theranostics for Triple-Negative Breast Cancer

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Jan 21

PMID 36673082

Authors

Hyeryeon Choi

Kwangsoon Kim

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.

Citing Articles

Value of Carbon-Ion Radiation Therapy for Breast Cancer.

Yu B, Li K, Fan Y, Pei X Int J Part Ther. 2024; 14:100629.

PMID: 39309411 PMC: 11415881. DOI: 10.1016/j.ijpt.2024.100629.

Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress.

Haidar M, Rizkallah J, El Sardouk O, Ghawi N, Omran N, Hammoud Z Diagnostics (Basel). 2024; 14(17).

PMID: 39272726 PMC: 11394464. DOI: 10.3390/diagnostics14171943.

The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date).

Ndongwe T, Zhou A, Ganga N, Matawo N, Sibanda U, Chidziwa T Discov Nano. 2024; 19(1):138.

PMID: 39225730 PMC: 11372008. DOI: 10.1186/s11671-024-04089-3.

Biogenic nanoparticles: pioneering a new era in breast cancer therapeutics-a comprehensive review.

Bhat S, Kumar V, Dhanjal D, Gandhi Y, Mishra S, Singh S Discov Nano. 2024; 19(1):121.

PMID: 39096427 PMC: 11297894. DOI: 10.1186/s11671-024-04072-y.

Recent Progress of Multifunctional Molecular Probes for Triple-Negative Breast Cancer Theranostics.

Zhao D, Li Z, Ji D, Xia Q Pharmaceutics. 2024; 16(6).

PMID: 38931924 PMC: 11207493. DOI: 10.3390/pharmaceutics16060803.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Medina M, Oza G, Sharma A, Arriaga L, Hernandez Hernandez J, Rotello V . Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health. 2020; 17(6). PMC: 7143295. DOI: 10.3390/ijerph17062078. View

Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Chang C . Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2018; 5(3):334-342. PMC: 6439843. DOI: 10.1001/jamaoncol.2018.5152. View

Echavarria I, Lopez-Tarruella S, Picornell A, Garcia-Saenz J, Jerez Y, Hoadley K . Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res. 2018; 24(8):1845-1852. PMC: 5899625. DOI: 10.1158/1078-0432.CCR-17-1912. View

Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y . EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 2009; 21(2):413-7. View

Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee A . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15):1949-55. DOI: 10.1200/JCO.2010.30.5037. View

Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A . Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One. 2012; 7(2):e31070. PMC: 3280290. DOI: 10.1371/journal.pone.0031070. View

Michalet X, Pinaud F, Bentolila L, Tsay J, Doose S, Li J . Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307(5709):538-44. PMC: 1201471. DOI: 10.1126/science.1104274. View

Su Y, Burnouf P, Chuang K, Chen B, Cheng T, Roffler S . Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat Commun. 2017; 8:15507. PMC: 5472176. DOI: 10.1038/ncomms15507. View

10.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

11.

Mukherjee S, Ray S, Thakur R . Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2010; 71(4):349-58. PMC: 2865805. DOI: 10.4103/0250-474X.57282. View

12.

Pfeiffer R, Webb-Vargas Y, Wheeler W, Gail M . Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev. 2018; 27(10):1214-1222. PMC: 8423092. DOI: 10.1158/1055-9965.EPI-18-0098. View

13.

Chen X, Li J, Gray W, Lehmann B, Bauer J, Shyr Y . TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform. 2012; 11:147-56. PMC: 3412597. DOI: 10.4137/CIN.S9983. View

14.

Schott A, Landis M, Dontu G, Griffith K, Layman R, Krop I . Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013; 19(6):1512-24. PMC: 3602220. DOI: 10.1158/1078-0432.CCR-11-3326. View

15.

Eskiler G, Cecener G, Dikmen G, Egeli U, Tunca B . Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro. Curr Drug Deliv. 2019; 16(6):511-529. DOI: 10.2174/1567201816666190515105532. View

16.

Jain A, Mahira S, Majoral J, Bryszewska M, Khan W, Ionov M . Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer. J Biomed Mater Res A. 2019; 107(9):1933-1944. DOI: 10.1002/jbm.a.36701. View

17.

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

18.

Fathy Abd-Ellatef G, Gazzano E, Chirio D, Hamed A, Belisario D, Zuddas C . Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics. 2020; 12(2). PMC: 7076516. DOI: 10.3390/pharmaceutics12020096. View

19.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View